The properties about to test Collingwood's cool credentials
At the time of AEW's off-market purchase, the 19,213 sq m building was raking in $10 million a year in rent giving the deal a tight 4.9 per cent yield.
While not giving much away, AEW says it has achieved a 52.8 per cent increase in rental income in the six years it has owned the tower. It's understood that's on a fully leased basis, and the tower's occupation rate is currently about 83 per cent with new tenants still taking up space.
CBRE's Kiran Pillai, Scott McGlone and Nikola Jackson with Cushman & Wakefield's Leigh Melbourne, Nick Rathgeber, Josh Cullen and Morgan Briscoe have charge of the listing.
'Thirty-one Queen Street has been a dominant performer in the leasing market over the past three to four years, underpinned by one of the best examples of a ground-up refurbishment,' Pillai said.
'Given the asset's exceptional fundamentals, central-CBD location and low-risk cashflow, we expect strong interest from high-net-worth privates, syndicators and funds,' Melbourne said.
The decline in CBD values appears to have bottomed out with a series of big-game bargain hunters, ranging from cashed-up locals to offshore behemoths lured back to the market.
Hong Kong private equity property company PAG is understood to be running the ruler over Dexus' Flinders Gate complex. Its current book value stands at $265.5 million with Dexus is reportedly hoping for around $260 million.
Last year PAG snagged 367 Collins Street for $340 million from Mirvac, a 20 per cent discount to its peak value.
The move also comes as Singapore-listed Frasers Logistics & Commercial Trust revealed it had sold 357 Collins Street to Harry Stamoulis for $195.3 million.
The final price – about current book value – will clock in at $192 million, after lease incentive liabilities are paid out. Frasers paid a staggering $222.5 million 10 years ago.
Heavy lifting on High
Developers are expected to swoop on a huge building on Armadale's swanky High Street. The building which houses Armadale's Goodlife Gym at 1216-1230 High Street, comes with a price guide of $25-$30 million.
The property is on a 1926 sq m parcel of land stretching back to Willis Street at the rear. Records show the Tauber family paid $1.62 million for the property in 1986. The gym includes a pool.
Packed to the eyeballs with frock shops, bridal boutiques, cafes and homewares, High Street has a vacancy rate of just 2.3 per cent, according to Fitzroys' retail vacancy report, Walk the Strip, with rents commanding as much as $2000 a square metre.
Last year, the auction of 1047-1051 High Street dragged on for two hours with 900 bids volleyed between two parties. The corner double-storey office and shop, on 500 sq m of land, eventually sold for $11.4 million.
The Goodlife building is for sale through Cushman & Wakefield's Daniel Wolman, Oliver Hay, Hamish Burgess and Leon Ma with Teska Carson's Matthew Feld.
There's a bit of choice on the strip at the moment. Lawyer and investor Peter Mitrakas is selling a 1585 sq m parcel of land at 23-27 Osment Street near Armadale Station for about $20 million.
And five strata owners at 1097-1111 High Street are hoping to sell their building – on a large 1733 sq m site on the corner of Huntingtower Road – for about $30 million.
East Melbourne
A local private investor has paid about $13.5 million for the old Melbourne IVF fertility clinic at 344 Victoria Parade, a much-storied building in East Melbourne's medical precinct which won awards when it was built in the early 1990s.
While the vendor, veteran investment group Henkell Brothers, was seeking closer to $15 million for the three storey-office, it nonetheless made a tidy profit.
Henkell Brothers bought the 2444 sq m building from the late Richard Pratt's Pratt Industries in 1995 for just $3.92 million – after it passed in at a mortgagee auction for $2.9 million.
It was a bargain even at the time. The Victorian Public Service Association had been ready to pay $7.12 million for the city-fringe office, but the deal fell through after the sale of its CBD office to theatre impresario David Marriner collapsed.
CBRE agents Nick Peden, Sandro Peluso, Jamus Campbell and Mark Granter negotiated the deal.
'The campaign attracted significant interest, with several unconditional offers received from both local and international investors – an unprecedented result for a vacant property,' Peden said.
The building had been the home of Melbourne IVF's fertility clinic for many years but the baby-maker is off to Hines' new 15-storey timber building, T3 at 36 Wellington Street, across the road.
AirHub
Growthpoint Properties is testing the market's appetite for industrial investments offering up a six-property portfolio at Melbourne Airport.
The AirHub portfolio, currently on Growthpoint's books with a $127 million value, covers a 25-hectare chunk of land around the airport with net lettable space of 139,707 sq m.
They're being offered individually or as a job lot. Tenants include Australia Post, Unipart Group, Direct Couriers and Laminex.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


West Australian
7 hours ago
- West Australian
Solara defines high-priority drill targets at DeGrussa West
Solara Minerals has locked onto two compelling copper-gold targets at its DeGrussa West project in Western Australia's Bryah Basin, just 17km along strike from Sandfire Resources' historic DeGrussa mine and 10km from Catalyst Metals' Old Highway gold deposit which hosts 206,000 ounces of gold. The company's recent moving loop electromagnetic (MLEM) survey outlined two major north-dipping conductors interpreted to represent mineralised structures. One is a western 700m-long plate while the other lies in the east and extends over a distance of 1300m. Both are situated at the highly prospective contact between the Narracoota Volcanics and the Karalundi Formation which are considered to be equivalent to the prospective DeGrussa Formation and coincide with strong magnetic anomalism. The 65 square kilometre DeGrussa West project sits inside the prolific Bryah Basin of Western Australia's Murchison region, a geological address well-known for hosting significant copper-gold deposits. Historical exploration of the project area includes a 2009 airborne VTEM survey by Sandfire which identified untested bedrock conductors in the same geological sequence as its massive DeGrussa operation. Solara's recent MLEM survey has refined those old conductors, showing they cut across the south-dipping Bryah Basin stratigraphy and link up with magnetic highs and structural breaks including a northeast-trending fault – classic hallmarks of a potentially fertile system in the region. Rock chip and soil sampling, although limited, show anomalous gold values up to 345 parts per billion (ppb), accompanied by elevated copper, zinc, arsenic, and other element signatures, further supporting the inferred mineralisation potential of the ground. The project's structural setting and stratigraphy are reminiscent of Sandfire's DeGrussa system, with fold hinges and fault intersections offering prime focal points for mineralisation. Solara considers the western conductor to be the more prospective of the two, but both are slated for upcoming drill testing. Previous exploration by Barrick between 2000 and 2005 and by Ausgold Exploration between 2011 and 2019 included soil sampling and VTEM surveys. Those surveys also identified conductive zones that point to a volcanogenic massive sulphide-style of mineralisation, similar to that at the old DeGrussa operation, but many of those high quality targets remain untested. Solara has already secured a program of work approval and is preparing for site visits and surface exploration ahead of its maiden drilling program. Initial holes will test where geophysics and structure converge, with an eye on unlocking a new copper-gold system in the heart of the Bryah Basin. With its strategic position next to major deposits, a textbook geological setting and compelling geophysical hits, Solara looks primed to drill into what could be a DeGrussa-style copper-gold system hiding in plain sight. Is your ASX-listed company doing something interesting? Contact:


West Australian
13 hours ago
- West Australian
‘Low confidence' in Kwinana as IGO left with no choice but to scrub value off ailing lithium refinery
IGO has determined any value left in a troubled lithium hydroxide train at Kwinana will now need to be written off, with chief executive Ivan Vella declaring outright the miner has little faith in its future. More downtime and equipment failures meant the struggling operation was running at just 35 per cent of its capacity during the quarter and will not meet its targeted production for the year. IGO also had to fork out another $4.5 million in recent months to sustain the refinery, which still copped an even bigger earnings before interest, tax, depreciation and amortisation loss for the period of $28.7m. Mr Vella made it clear on Wednesday the miner was running out of patience with the operation, though it remained unclear in the results whether IGO and its joint venture partner Hong Kong-listed lithium developer Tianqi would make the call to shut up shop. After the dire quarter in Kwinana, IGO said another $70m to $90m would need to be scrubbed from the value of its main lithium production unit, meaning the operation will likely be fully impaired on the books for the full year. It adds to the $525m erased from the value of Train 1 in January, when IGO also called off plans to build a second processing train at the site due to weak lithium prices. 'Despite the strong commitment from the team at site to address operational problems and ongoing issues, IGO has low confidence in the ability of this asset to achieve meaningful, sustained improvement,' the CEO told the market on Wednesday. 'We continue to work with our JV partner to determine the optimal future pathway for the plant.' Greenbushes was yet again IGO's saving grace, with the South West lithium mine making sales of 412,000 tonnes of spodumene concentrate for the period, an improvement of 12 per cent on the prior quarter. Costs and production targets were both within guidance for the full year. More to come.

News.com.au
17 hours ago
- News.com.au
ASX Health Quarterly Wrap: Dimerix inks fourth licensing deal, Audeara nails record revenue year
As the quarterly reporting season kicks into gear, investors are again tuning in to see how ASX-listed companies fared over the final stretch of FY25 and what clues they're offering for the financial year ahead. It's a key moment for investors to assess how businesses are tracking and what lies ahead, especially for the long-suffering healthcare sector, which has lagged in recent years despite strong fundamentals. After falling 4% over FY25 – while the broader market climbed 10% – there are signs the tide may finally be starting to turn. The S&P/ASX 200 Health Care index (ASX:XHJ) jumped 5.4% last week following a 5% gain the week before, sparking talk of a rotation back into the sector. Throughout FY25 and during the last quarter many ASX healthcare names have taken steps to improve efficiency, reduce costs, advance trials or establish key partnerships in a bid for long-term growth. Here's how a selection of ASX health stocks performed in the June quarter and what they're signalling for FY26. Dimerix (ASX:DXB) Late-stage clinical biotech Dimerix continued to progress its lead program ACTION3 phase III clinical trial of DMX-200 in focal segmental glomerulosclerosis (FSGS) during the quarter, including a positive Type C meeting with the US Food and Drug Administration (FDA). The meeting confirmed acceptability of proteinuria as an appropriate endpoint for full marketing approval in the US for DMX-200 in FSGS. During the quarter Dimerix announced a licensing agreement for DMX-200 with Amicus Therapeutics for DMX-200 in the US, its fourth for the drug across multiple territories. The company banked an upfront payment of US$30 million (~A$48m) in May. Collectively the licensing deals provide up to ~$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales with more than $65m in total payments received to date. During the quarter Dimerix received its first development milestone payment of ¥400 million (~A$4.2m) from FUSO Pharmaceutical Industries Ltd, its exclusive licensee of DMX-200 for FSGS in Japan after the first trial site opened. Additionally, during the quarter, Dimerix received ~$6m from the exercise of listed options which expired on June 30. The sixth Independent Data Monitoring Committee (IDMC) review of ACTION3 has been completed, with 219 patients currently randomised/dosed in the trial. Dimerix ended the quarter with $68.3m. The company said it continued to focus on patient recruitment into ACTION3 trial, as well as licensing opportunities with potential partners in territories not already licensed. Audeara (ASX:AUA) Personalised audio technology provider Audeara achieved record full-year cash receipts of $4.9m, up 38.4% on FY24, driven by the expanding global sales profile for the AUA Technology division. Audeara achieved quarterly unaudited revenues of $722,000 with record-high unaudited annual revenues of ~$3.79m, up 21.9% on FY24. Cash receipts of $957,000 in Q4 FY25 were consistent with pcp of $982,000 and contributed to the record annual cash receipts. Quarterly group cash receipts were underpinned by accelerating momentum for Audeara's core domestic wholesale channel, which rose by 34.9% QoQ and 115% YoY. Net operating cash outflows of $757,000 were largely driven by strategic focus on R&D and stock purchasing. The company had $1.42m cash at bank as at June 30, 2025. Strategic inventory build is expected to flow through to increased net operating cash flows next quarter, with the start of product delivery for a follow-up purchase order by Avedis Zildjian. In its outlook Audera noted renewed momentum in its core wholesale markets was being supported by continued growth opportunities for AUA Technology across global markets. The Zildjian purchase order is expected to contribute to a significant increase in cash receipts for the September quarter, reflecting timing of payments. LTR Pharma (ASX:LTP) LTR Pharma kicked off a distribution partnership deal for its Spontan intranasal spray for erectile dysfunction (ED) with Symbion in May with initial pharmacy orders and prescriber feedback "encouraging, supporting broader market uptake in future quarters". Patients can now have Spontan prescriptions filled at Symbion's 3900 pharmacies Australia-wide. A pharmacy training program was delivered to Sympbion's pharmacists nationwide on Spontan's unique benefits and patient counselling. In May urologist associate professor Darren Katz was appointed to LTR Pharma's scientific advisory board, bringing extensive ED treatment expertise as medical director of Men's Health Melbourne and immediate past leader of USANZ Andrology Special Advisory Group. During the quarter LTR Pharma advanced its new ED product Roxus. As Spontan moves through the formal FDA process, Roxus offers a fast-track pathway to serve patients through personalised care channels. The company said development of a scalable, GMP-compliant manufacturing process for Roxus was being progressed in collaboration with its Australian pharmaceutical partner. Key formulation milestones have been achieved bringing Roxus closer to market readiness ahead of its planned US launch in H1 CY26 with manufacturing optimisation underway. In May LTR signed a collaborative development agreement with Strategic Drug Solutions (SDS) to develop Oroflow for oesophageal motility disorders, a debilitating group of conditions affecting swallowing function. The program leverages LTP's proven intranasal delivery platform and patent rights from Spontan and Roxus. LTR Pharma had a cash balance of $31.8m as at June 30, 2025, which it said provided substantial runway to execute strategic objectives across multiple markets. EZZ Life Science (ASX:EZZ) EZZ achieved a major strategic milestone during the quarter with the official launch of EZZDAY, a US-focused brand, with the initial product range including four FDA-registered health supplements. All four products are manufactured in the United States to align with consumer preferences, reduce tariffs and freight costs, and enhance supply chain efficiency. In June, EZZ entered a three-year distribution agreement with ROFA Enterprises, securing a minimum purchase value of A$21 million over the contract term. ROFA will distribute EZZ-branded products across Thailand, Vietnam and Singapore, managing local logistics and marketing, while ensuring compliance with EZZ's brand and operational standards. During the quarter EZZ expanded its domestic retail footprint via a new partnership with Australian pharmacy chain Direct Chemist Outlet. Under the agreement, EZZ's flagship products will be stocked in a selection of DCO's 130 stores nationwide. The company launched a new consumer health product EZZ Liquid Calcium Soft Gel for key international and domestic markets to further capitalise on its strong performance in the calcium supplement category. During the quarter EZZ engaged the University of Sydney to undertake a two-year in vitro research project into the effects of a novel multi-ingredient nutritional supplement on bone growth. Receipts from customers totalled $21.3m, representing a 46% increase from the previous quarter with a positive cash inflow of $1.4m. Cash reserves reached $20.8m as at 30 June 2025 after paying $900,000 in dividends during the quarter. EZZ remains debt-free, excluding lease liabilities.